問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chiayi Chang Gung Memorial Hospital of the C.G.M.F.

  • 0

    Total Beds

  • 0

    Total Doctors

  • 613Chiayi CountyChiayi Puzih

Recruiting Trial

43Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

171Cases

2010-06-01 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-08-01 - 2012-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2013-02-01 - 2020-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-06-01 - 2015-02-20

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-11-01 - 2014-11-01

Phase II

A Randomized, Double-Blind, Placebo-Controlled Trial of AC-201 In Subjects with Gout Initiating Urate-Lowering Therapy

  • Condition/Disease

    Gout

  • Test Drug

    AC-201

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

2008-01-01 - 2011-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-04-01 - 2019-03-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-04-01 - 2015-10-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2012-11-05 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

2012-10-02 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

1 12 13 14 15 16 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB